The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine and trastuzumab, in HER2+ metastatic breast cancer (MBC).
Erika Paige Hamilton
No relevant relationships to disclose
Denise A. Yardley
No relevant relationships to disclose
Gabriel N. Hortobagyi
Consultant or Advisory Role - Allergan; Antigen Express; Galena Biopharma; Genentech; Novartis; Pfizer; Sanofi
Research Funding - Novartis
Luke N. Walker
Employment or Leadership Position - Oncothyreon
Stock Ownership - Oncothyreon
Virginia F. Borges
No relevant relationships to disclose
Stacy L. Moulder
Research Funding - Array BioPharma